Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

MGF Igf-1-ec

IGF-1Ec, IGF-1Eb, Mechano-Growth Factor

Quick Stats
Studies 62
Trials 100
Completed NA INTERVENTIONAL NCT06850532

NMES Effects on Substrate Metabolism and IGF-1

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The aim of this study is to investigate whether neuromuscular electrostimulation (NMES) training coupled with high-intensity interval training (HIIT) and moderate intensity continuous aerobic training has an effect on the metabolic, cardiovascular and hormonal components compared to respective training protocols without concurrent NMES as a exercise performance enhancement strategy.

Interventions

Name: IGF-1
Type: OTHER
Description: The effects of NMES coupled with HIIT and MICT on IGF-1 and substrate metabolism has not been studied earlier.

Primary Outcomes

Measure: Body composition via Bioelectrical Impedance Analysis (Tanita 418-MA, Japan)
TimeFrame: From enrollment to the end of treatment at 8 weeks
Description: Weight (kg) Total body fat (kg) Total muscle mass (kg) The anthropometric parameters were assessed using Bioelectrical impedance analysis (Tanita 418- MA Japan) before all testing sessions.
Measure: Height (cm) via a stadiometer (Holtain Ltd., UK).
TimeFrame: From enrollment to the end of treatment at 8 weeks
Description: Height was measured through a stadiometer in the standing position (Holtain Ltd., Crymych, UK).
Measure: Heart rate (bpm) via 12-lead ECG
TimeFrame: From enrollment to the end of treatment at 8 weeks
Description: Heart rate was monitored and recorded throughout baseline and follow-up screenings and all training sessions using 12-lead ECG.
Measure: Blood Lactate Concentration (mmol/L) via Lactate Pro 2 analyzer
TimeFrame: From enrollment to the end of treatment at 8 weeks
Description: In each GXT testing session (pre-post), blood samples were collected from the earlobe using a Lactate Pro 2 handheld analyzer (LT-1730, Arkray Inc, Kyoto, Japan) to determine blood lactate concentrations testing session (baseline) and at the end of every two minutes interval.
Measure: SERUM INSULIN-LIKE GROWTH FACTOR-1 (IGF-1 ng/mL)
TimeFrame: From enrollment to the end of treatment at 8 weeks
Description: A 5 mL fasting blood sample was drawn from the brachial vein 30 minutes before baseline and follow-up IVO2max tests to measure serum IGF-1 concentrations. Participants rested for 15 minutes before sample collection. Samples were stored at -80 °C and analyzed post-study. Serum IGF-1 levels were measured using Elabscience ELISA kits (detection range: 1.56-100 ng/mL; sensitivity: 0.94 ng/mL) per the manufacturer's instructions.
Measure: VO2 - Volume of oxygen (ml/kg/min) VCO2 - Volume of carbon dioxide (ml/kg/min)
TimeFrame: From enrollment to the end of treatment at 8 weeks
Description: During all sessions, VO2 and VCO2 were measured using indirect calorimetry (CareFusion MasterScreen CPX) on an Ergoline Ergoselect 100/200 cycle ergometer. Data was averaged over 15-second intervals during all baseline and follow-up screenings and all training sessions. VO2 and VCO2 were also used to calculate respiratory exchange ratio (RER) during all sessions dividing the VCO2 by VO2.
Measure: Energy expenditure (L/min) via indirect calorimetry (CareFusion MasterScreen CPX).
TimeFrame: From enrollment to the end of treatment at 8 weeks
Description: During all sessions, energy expenditure was measured using indirect calorimetry (CareFusion MasterScreen CPX). Data was averaged over 15-second intervals, and substrate utilization was calculated using standard formulas. * (GOR)- Oxidation rate of sugar (g/min): 4.585 × VCO2 (L/min) -3.2256 × VO2 (L/min) * (GO)- Oxidation amount of sugar (g): Oxidation rate of sugar × Time (min) * (FOR)- Fat oxidation rate (g/min): 1.695 × VO2 (L/min) -1.701 × VCO2 (L/min) ④ (FO)- Oxidation amount of fat (g): Oxidation rate of fat × Time (min) * (EER)- Energy consumption rate (kcal/min): 3.716 × VO2 (L/min) +1.332 × VCO2 (L/min) ⑥ (EE)- Energy expenditure (kcal): \[3.716 × VO2 (L/min) +1.332 × VCO2 (L/min)\] × Time (min)
Measure: Neuromuscular Electrical Stimulation (NMES) Protocol
TimeFrame: From enrollment to the end of treatment at 8 weeks
Description: The NMES protocol was administered via a four-channel COMPEX SP4.0 (Medicompex SA, Ecublens, Switzerland) electric muscle stimulator using biphasic symmetric rectangular pulsed currents set at 300 μs. COMPEX self-adhesive electrodes were used during muscle stimulation with the COMPEX device. Positive snap electrodes (5×5 cm) with a membrane depolarization that stimulate a 25 cm2 area of the muscle surface were placed on the proximal insertion of vastus medialis and vastus lateralis. The other negative electrode (10×5 cm), measuring 50 cm2 was placed over the femoral triangle, 1-3 cm below the inguinal ligament.
Measure: Low-frequency Neuromuscular Electrical Stimulation (NMES)
TimeFrame: From enrollment to the end of treatment at 8 weeks
Description: The low-frequency NMES protocol was administered via a four-channel COMPEX SP4.0 (Medicompex SA, Ecublens, Switzerland) electric muscle stimulator using biphasic symmetric rectangular pulsed currents set at 200 μs. Low-frequency NMES protocol was performed with a duty cycle of 20 seconds on (stimulating) and 20 seconds off (no stimulation) and the pulse width was set at 300 μs (warm-up frequency: 3 Hz, training frequency: 20 Hz, wave: square waveform) to the quadriceps muscle throughout 24 sessions. The duration of training was 30 minutes for sessions 1-6, 36 minutes for sessions 7-12, 42 minutes for sessions 13-18, and 48 minutes for sessions 19-24.
Measure: High-frequency Neuromuscular Electrical Stimulation (NMES)
TimeFrame: From enrollment to the end of treatment at 8 weeks
Description: High-frequency NMES protocol was administered via a four-channel COMPEX SP4.0 (Medicompex SA, Ecublens, Switzerland) electric muscle stimulator using biphasic symmetric rectangular pulsed currents set at 300 μs. High-freqeuncy NMES protocol consisted of a 5-minute warm-up (65% VO2max) followed by a 1-minute exercise at 120% VO2max and then a 1-minute "loadless" cycling. This interval was repeated 8 times in sessions 1-6 and progressed to 14 repeated intervals by the 24th session. Participants also received an additional NMES treatment with a duty cycle of 12 seconds on (stimulating) and 8 seconds off (no stimulation) and a pulse width of 300 μs (training frequency: 45-60 Hz, wave: square waveform) to the quadriceps muscle throughout 24 sessions.

Trial Information

NCT ID

NCT06850532

Status

Completed

Study Type

INTERVENTIONAL

Phases

NA

Sponsor

Mersin University

Last Updated

December 15, 2025

Related Peptides